Veracyte, Inc.

25.25 USD
-0.44 (-1.71%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Veracyte, Inc. stock is up 5.16% since 30 days ago. The next earnings date is Feb 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 December’s closed higher than November. 50% of analysts rate it a buy.

About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas. It is also developing Percepta Genome Atlas to help inform lung cancer treatment decisions.

  • Morgan Stanley
    Fri Nov 10, 09:25
  • Needham
    Wed Nov 8, 17:01